| Literature DB >> 18404417 |
Alma N Guerra1, Monica L Gavala, Hun Sun Chung, Paul J Bertics.
Abstract
Elevated levels of extracellular nucleotides are present at sites of inflammation, platelet degranulation and cellular damage or lysis. These extracellular nucleotides can lead to the activation of purinergic (nucleotide) receptors on various leukocytes, including monocytes, macrophages, eosinophils, and neutrophils. In turn, nucleotide receptor activation has been linked to increased cellular production and release of multiple inflammatory mediators, including superoxide anion, nitric oxide and other reactive oxygen species (ROS). In the present review, we will summarize the evidence that extracellular nucleotides can facilitate the generation of multiple ROS by leukocytes. In addition, we will discuss several potential mechanisms by which nucleotide-enhanced ROS production may occur. Delineation of these mechanisms is important for understanding the processes associated with nucleotide-induced antimicrobial activities, cell signalling, apoptosis, and pathology.Entities:
Year: 2007 PMID: 18404417 PMCID: PMC2096761 DOI: 10.1007/s11302-006-9035-x
Source DB: PubMed Journal: Purinergic Signal ISSN: 1573-9538 Impact factor: 3.765
Summary of extracellular nucleotide regulation of ROS production by immune and tumor cells
| Cell type | Treatments* | Nucleotide effect on ROS production* | Receptors proposed | Method for measuring ROS production | References |
|---|---|---|---|---|---|
| Human neutrophils | fMLP + ATP, ADP, or AMP | ATP or ADP: ↑ | Not discussed | SOD-sensitive reduction of ferricytochrome c | [ |
| AMP: ↑ | |||||
| Immune complex + ATP, ADP, or AMP | ATP, ADP, or AMP: ↑ | ||||
| Rat peritoneal neutrophils | fMLP + ATP, ADP, or AMP | ATP or ADP: ↑ | Not discussed | Ferrithiocyanate formation ± ferricytochrome c ± SOD | [ |
| Immune complex + ATP, ADP, or AMP | ATP, ADP, or AMP: ↑ | ||||
| Human or rat blood neutrophils | fMLP or immune complex + ATP | ATP: ↑ | |||
| Human neutrophils | fMLP + ATP, UTP, or ITP | ATP, UTP, or ITP: ↑ | None identified | Ferricytochrome c reduction assay | [ |
| Human HL 60 cells (promyelocytic leukemia cells) | ATP, ADP, dATP, UTP, dUTP, UDP, ITP, CTP, or TTP | ATP or UTP: ↑ | P2 receptors | SOD-sensitive reduction of ferricytochrome c | [ |
| Human neutrophils | ATP | ATP: ↑ | Not discussed | Ferricytochrome c reduction assay | [ |
| Rat alveolar macrophages | ATP, ADP, AMP, or ATPγS | ATP, ADP, or ATPγS: ↑ | 2 or more P2 receptor classes | SOD-sensitive reduction of ferricytochrome c | [ |
| Human eosinophils | ATP, ATPγS, 2-MeS-ATP, UTP, GTP, ADP, BzATP, or CTP | ATP, ATPγS, 2-MeS-ATP, UTP, GTP, or BzATP: ↑ | P2Y and P2X receptors | Lucigenin-dependent chemi-luminescence | [ |
| oATP or KN62: ↑ | |||||
| Human neutrophils and promyelocytes (HL-60 cells) | BzATP | BzATP: ↑ | P2X7 | DCFDA fluorescence (intracellular ROS) | [ |
| Human DU145 cells (prostate cancer) | ATP, ADP, UTP, or 2-MeS-ATP | ATP, ADP, UTP, or 2-MeS-ATP: ↑ | P2 receptors | DCFDA fluorescence (intracellular ROS) | [ |
| Rat mesangial cells | BzATP | BzATP: ↑ | P2X7 | DCFDA fluorescence (intracellular ROS) | [ |
| Rat microglia | BzATP or ATP | BzATP or ATP: ↑ | P2X7 | SOD-sensitive reduction of ferricytochrome c; tetrazolium dye reduction; translocation of p67 | [ |
| Human ARO cells (thyroid cancer) | ATP | ATP: ↑ | P2Y | DCFDA fluorescence (intracellular ROS) | [ |
| Murine RAW 264.7 macrophages | BzATP, ATP, UTP, or αβ-Methylene-ATP | BzATP or ATP: ↑ | P2X7 | DCFDA fluorescence (intracellular ROS) | [ |
* The upward arrow (↑ indicates that the specified treatment enhanced the indicated parameter (ROS production), whereas the downward arrow (↑ designates that the specified treatment or inhibitor (e.g., oATP or KN-62) attenuated ROS production. SOD superoxide dismutase, DCFDA the intracellular ROS-reactive indicator dye- 2–7–dichlorodihydrofluorescein diacetate.
Summary of extracellular nucleotide regulation of iNOS expression and NO production by immune cells
| LPS-stimulated event and system studied | Nucleotide and effect* | References |
|---|---|---|
| Nitric oxide (NO) production | ||
| LPS+ IFNγ-treated murine (CD-1) peritoneal macrophages | 2-MeS-ATP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | oATP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | ADP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | ATP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | ATP or BzATP: ↑ | [ |
| LPS-treated rat astrocytes | ATP, ADP, AMP, UTP, BzATP, or 2-MeS-ATP: ↑ | [ |
| oATP: ↑ | ||
| IFNγ-treated BV-2 murine microglia cells | ATP, ADP, BzATP, or 2-MeS-ATP: ↑ | [ |
| IL-1β/IFNγ-treated human astrocytes | BzATP: ↑ | [ |
| iNOS expression | ||
| LPS-treated RAW 264.7 murine macrophages | ATP: ↑ | [ |
| LPS+ IFNγ-treated murine (CD-1) peritoneal macrophages | 2-MeS-ATP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | PPADS: ↑oATP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | BzATP: ↑ | [ |
| LPS-treated RAW 264.7 murine macrophages | ATP: ↑ | [ |
| IFNγ-treated murine BV-2 microglia cells | BzATP or ATP: ↑ | [ |
* The upward arrow (↑ indicates that the specified nucleotide enhanced the indicated parameter (NO production or iNOS expression), whereas the downward arrow (↑ designates that the specified nucleotide or inhibitor attenuated the indicated parameter.
Fig. 1Working model for the involvement of P2X and P2Y receptors in regulating the phagocytic NADPH oxidase complex. In the resting state, a small portion of gp91 (Nox2) and p22 are located at the plasma membrane (although priming with factors such as LPS or chemoattractants can recruit additional gp91 and p22 to the membrane and promote the assembly of the NADPH complex (see text)). The oxidase function of the gp91/p22 is dormant until it is complexed with the cytosolic components p67, p47, p40, and Rac1/2. Stimulus-induced phosphorylation of p47 results in a conformational change that allows it to be recruited to the membrane and additional phosphorylation of the p47/p40/p67 complex allows for its structural reorganization and assembly with gp91/p22 at the membrane. Also, stimulus-induced recruitment of activated (GTP-loaded) Rac2 to the membrane facilitates the assembly of the functional NADPH oxidase complex. With respect to phox protein phosphorylation, several kinases are postulated to be important, including PKC isoforms and p38 MAP kinase. Also, Ca++ fluxes can promote NADPH oxidase assembly, in part via Ca++-dependent activation of kinases (e.g., PKC isoforms). Moreover, Rac activation may also contribute to phox protein phosphorylation via initiating p38 MAP kinase activation. Final assembly/activation of the NADPH complex requires additional phosphorylation steps. In terms of P2X and P2Y receptor-associated activation of NADPH oxidase activity, it is hypothesized that increases in intracellular Ca++ induced by P2X agonists result in the activation of protein kinases, such as PKC isoforms, that are essential for the phosphorylation/activation of NADPH oxidase subunits including p47. Furthermore, activation of P2X7 has been linked to the stimulation of p38 MAP kinase, which would also be expected to facilitate the phosphorylation/activation of NADPH oxidase subunits. In the case of P2Y receptors, many of these receptors can regulate certain phospholipase C (PLC) isoforms with the subsequent conversion of phosphoinositide-4,5-bisphosphate (PIP2) to IP3 and diacylglycerol (DAG), which in turn would lead to the elevation of cytoplasmic free Ca++ and the activation of PKC isoforms, respectively. These events would also be expected to promote the phosphorylation/activation of NADPH oxidase subunits. Furthermore, certain P2Y receptors have also been reported to lead to Rac activation, which in turn would be predicted to facilitate the phosphorylation, activation and assembly of NADPH oxidase